RespireRx Pharmaceuticals Inc (fka RSPI)

[enemem]

I'm glad it's done, but the data aren't that great. First, less than half of the subjects who got the drug showed improvement in either AHT or AHI, and there was an improvement in blood gas variables (it's unclear if these numbers are for everybody or for a subgroup).

The problem here is that the subjects who took the drug slept less. This is the most robust finding of the study (p<0.001).

What we have here is a drug that marginally reduces apnea, but robustly reduces sleep, a problem that I foresaw at the very start of this adventure.

I hope that the market reacts favorably. Whatever the reaction, I am glad this is behind us. I am curious about whether others think these results are consistent with a partnerable indication.